NovoCure: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Oct. 29, 2026, NovoCure (NASDAQ:NVCR) announced record quarterly net revenue of $193 million and raised its full-year top-line guidance. The oncology device maker is nearing sustained profitability as patient adoption expands across core markets. Three things management said stand out. Adoption of Optune Gio for glioblastoma, an aggressive brain cancer, pushed third-quarter net revenue up 16% year over year while delivering $16 million in adjusted EBITDA, which measures earnings before interest, taxes, depreciation, amortization, and share-based compensation. Commercial expansion in Japan for Optune Lua, a non-small cell lung cancer treatment, generated $4 million in third-quarter net revenue with monthly reimbursement pricing matching established global levels. Continue reading